Akademik Veri Yönetim Sistemi
Yeni Symposium, cilt.45, sa.1, ss.28-34, 2007 (Scopus)
Purpose: This study aims to compare the use of reboxetine + sertraline, which according to our thought would create a "dual effect" via both serotonin and noradrenalin, and venlafaxine which is a Selective Serotonin and Noradrenalin Reuptake Inhibitor (SNRI) in the treatment of the loss of social functioning in Major Depressive Disorder (MDD). Method: The study recruited 40 patients who met the DSM-IV MDD diagnostics criteria and who were compatible with the study protocol. These patients were randomized into two groups receiving sertraline+reboxetine and venlafaxine. Throughout the study period of 11 weeks the patients were evaluated six times, and at each evaluation "Hamilton Depression Rating Scale" (HAM-D), "Montgomery and Asberg Depression Rating Scale" (MADRS), and "Social Adaptation Self-evaluation Scale (SASS) were performed. Findings: In both medicine groups, the changes in HAM-D, HAM-D 7th item, MADRS and SASS scores was found to be statistically significant starting from the 2nd visit (p<0.05) compared to the values prior to medication. Percent changes of HAM-D 7th item, MADRS and SASS over time according to pre-medication values did not show any statistically significant difference between the medicine groups of reboxetine+sertraline and venlafaxine. However, the percent decrease in venlafaxine group in HAM-D scale was found to be significantly higher compared to the reboxetine+ sertraline group at visit 3. Discussion and Conclusion: Assuming that a similar effect would be provided as that of venlafaxine which is known to create a "dual effect" via serotonin and noradrenalin, two groups of patients on medication of reboxetine+sertraline were compared in this study. However, it was found that there was no difference between the approaches of treatment as far as efficacy and remission in social functioning were concerned.